-->

Phospho-SHP2 (Tyr542) cellular kit HTRF®

The phospho-SHP2 (Tyr542) kit enables the cell-based quantitative detection of phosphorylated SHP2 as a result of cell surface receptor activation, especially checkpoint inhibitor receptors in T cells.

See more
  • All inclusive kit All inclusive kit
  • High sensitivity High sensitivity
  • No-wash No-wash
  • Low sample consumption Low sample consumption

The phospho-SHP2 (Tyr542) kit enables the cell-based quantitative detection of phosphorylated SHP2 as a result of cell surface receptor activation, especially checkpoint inhibitor receptors in T cells.

-

Overview

This cell-based assay is designed to monitor the phosphorylation of SHP2 on Tyr542, which represents a hallmark of its activation.

Many cancer cells overexpress checkpoint inhibitor ligands such as PD-L1. PD-L1 binds its counterpart checkpoint inhibitor receptor PD1, present at the surface of T lymphocytes. In turn, the PD1-PDL1 complex recruits and activates inhibitory effectors, such as SHP1 or SHP2. These two phosphatases, which are phosphorylated on Tyr564 and Tyr542 respectively by the kinase Lck, trigger the dephosphorylation of signaling proteins such as ZAP-70 or SLP-76, involved in the T cell activation pathway. Finally, activated SHP1 and SHP2 participate in T cell inactivation.

Preventing activation of SHP1 and/or SHP2 by small molecule inhibitors is believed to contribute to restoring the immune response against tumors.

Benefits

  • SPECIFICITY
  • PRECISION

Phospho-SHP2 (Tyr542) assay principle

The Phospho-SHP2 (Tyr542) assay measures SHP2 when phosphorylated at Tyr542. Unlike Western Blot, the assay is entirely plate-based and does not require gels, electrophoresis, or transfer. The Phospho-SHP2 (Tyr542) assay uses 2 labeled antibodies, one with a donor fluorophore, and the other with an acceptor. The first antibody is selected for its specific binding to the phosphorylated motif on the protein, the second for its ability to recognize the protein independent of its phosphorylation state. Protein phosphorylation enables an immune-complex formation involving both labeled antibodies and which brings the donor fluorophore into close proximity to the acceptor, thereby generating a FRET signal. Its intensity is directly proportional to the concentration of phosphorylated protein present in the sample, and provides a means of assessing the protein's phosphorylation state under a no-wash assay format.

phospho-shp2-y542-assay-principle

Phospho-SHP2 (Tyr542) two-plate assay protocol

The two-plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates to a 384-well low volume detection plate before adding Phospho-SHP2 (Tyr542) HTRF detection reagents. This protocol enables the cells' viability and confluence to be monitored.

phospho-shp2-y542-2-plate-assay-protocol

Phospho-SHP2 (Tyr542) one-plate assay protocol

Detection of Phosphorylated SHP2 (Tyr542) with HTRF reagents can be performed in a single plate used for culturing, stimulation, and lysis. No washing steps are required. This HTS designed protocol enables miniaturization while maintaining robust HTRF quality.

phospho-shp2-y542-1-plate-assay-protocol

In Jurkat cells, SHP2 phosphorylation is detected in the presence of pervanadate

Human Jurkat suspension cells were plated at 100,000 cells/well in a 96 well half area plate and incubated for 30 min in the presence or absence of Pervanadate at 30µM. Following this incubation, cells were lysed with 10µL of 4X supplemented lysis buffer for 30min at RT under gentle shaking. Then 16 µL of lysate were transferred into a 384-well low volume white microplate, and 4µL of the HTRF phospho-SHP2 (Tyr542) detection reagents were added. The HTRF signal was recorded after an overnight incubation.

In Jurkat cells, SHP2 is transiently phosphorylated, thus making its detection difficult. By inhibiting phosphatases activity, pervanadate prevents the rapid dephosphorylation of SHP2 and enables a clear detection of phosphorylated SHP2.
Image showing the importance of Pervanadate to detect Phospho-SHP2 Tyr564

Pharmacological validation using the Lck inhibitor, saracatinib, in Jurkat T-cells

Human Jurkat suspension cells were plated at 100,000 cells/ well in a 96 well half area plate, and incubated for 24h at 37°C, 5% CO2, with increasing concentrations of Saracatinib. Before lysis, Jurkat cells were incubated for 30 min with Pervanadate 30 µM followed by the addition of 10µL of supplemented lysis buffer 4X. After 30min lysis at RT under gentle shaking, 16µL of lysate were transferred into a 384-well low volume white microplate, and 4µL of the HTRF phospho-SHP2 (Tyr542) or total SHP2 detection reagents were added. The HTRF signal was recorded after a 4 hour incubation.

As described elsewhere, a dose dependent inhibition of SHP2 Tyr542 phosphorylation was obtained following treatment with Saracatinib, whereas the SHP2 expression level remained stable under the same experimental conditions.

Image of the validation of the HTRF phospho and total SHP2 assays on human Jurkat cells treated with Saracatinib and Pervanadate

Pharmacological validation on NIH-3T3 mouse cells stimulated with PDGF

Mouse NIH 3T3 adherent cells were seeded at 100,000 cells/ well in a 96-well plate and incubated at 37°C, 5% CO2. After an overnight serum deprivation, cells were stimulated with increasing concentrations of PDGF for 20 min. Cell culture medium was harvested, and cells were lysed with 50 µL supplemented lysis buffer. After 30min lysis at RT under gentle shaking, 16µL of lysate were transferred into a 384-well low volume white microplate, and 4µL of the HTRF phospho-SHP2 (Tyr542) or total SHP2 detection reagents were added. The HTRF signal was recorded after a 4 hour incubation.

As shown here, PDGF stimulation induced a strong SHP2 Tyr542 phosphorylation in NIH3T3 cells, whereas SHP2 expression remained stable under the same experimental conditions.

Image of the validation of the HTRF phospho and total SHP2 assays on mouse NIH 3T3 cells treated with PDGF

HTRF assay compared to Western Blot

The human Jurkat cell line was seeded in a T175 flask, and incubated at 37 °C, 5% CO2. The cells were then treated with Pervanadate (30 µM) for 30 min before lysis.

Serial dilutions of the cell lysate were performed in the supplemented lysis buffer, and 16 µL of each dilution were transferred into a low volume white microplate before the addition of 4 µL of HTRF phospho-SHP2 detection reagents. Equal amounts of lysates were used for a side by side comparison between HTRF and Western Blot.

Using the HTRF Phospho-SHP2 Y542 assay, 620 cells/well were sufficient to detect a signal, while 10,000 cells were needed using Western Blot relying on ECL detection. These results demonstrate that the HTRF phospho-SHP2 assay is 16 times more sensitive than the Western Blot.
Image of the comparison between Western blot and HTRF using phospho-SHP2 on human Jurkat cells treated with Pervanadate

Function and regulation of SHP2

SHP1 (also known as tyrosine-protein phosphatase non-receptor type 6, PTPN6) is a tyrosine phosphatase mainly expressed in hematopoietic cells, activated by Lck and recruited by cellular surface receptors. SHP2 (also known as tyrosine-protein phosphatase non-receptor type 11) is ubiquitously expressed in hematopoietic or non-hematopoietic cells. Although SHP2 negatively regulates T cell activation, SHP2 is positively involved in ERK activation in response to growth factors such as PDGF or FGF.

In T lymphocyte cells, SHP1 and 2 are recruited by immune checkpoint inhibitors, thereby participating in the suppression of the TCR signaling pathway. SHP1 and 2 interact with PD1 ITIM domains and are phosphorylated and activated by the Lck kinase. Activated SHP1 and 2 phosphatases lead to the dephosphorylation of key TCR signaling effectors such as ZAP70 or SLP76, which are required for T-cell proliferation and function.

Pathway Phospho SHP2

HTRF phospho-assays reveal subtle drug-induced effects

Detailed protocol and direct comparison with WB - Posters

HTRF® cell signaling platform combined with iCell® Hepatocytes

A solution for phospho-protein analysis in metabolic disorders - Posters

Key guidelines to successful cell signaling experiments

Mastering the art of cell signaling assays optimization - Guides

Optimize your HTRF cell signaling assays on tissues

HTRF and WB compatible guidelines - Technical Notes

HTRF Alpha-tubulin Housekeeping kit

Properly interpret your compound effect - Application Notes

Best practices for analyzing brain samples with HTRF® phospho assays for neurosciences

Insider Tips for successful sample treatment - Technical Notes

HTRF phospho-total lysis buffer: a universal alternative to RIPA lysis buffers

Increased flexibility of phospho-assays - Application Notes

HTRF cell-based phospho-protein data normalization

Valuable guidelines for efficiently analyzing and interpreting results - Application Notes

HTRF phospho assays reveal subtle drug induced effects in tumor-xenografts

Tumor xenograft analysis: HTRF versus Western blot - Application Notes

Best practices for analyzing tumor xenografts with HTRF phospho assays

Protocol for tumor xenograft analysis with HTRF - Technical Notes

Unleash the potential of your phosphorylation research with HTRF

Unmatched ease of use, sensitivity and specificity assays - Videos

How to run a cell based phospho HTRF assay

What to expect at the bench - Videos

TCR signaling investigation with HTRF phospho assays

Study a pathway of interest in PBMC and T cells - Application Notes

Universal HTRF® phospho-protein platform: from 2D, 3D, primary cells to patient derived tumor cells

Analysis of a large panel of diverse biological samples and cellular models - Posters

Simplified pathway dissection with HTRF phospho-assays and CyBi-felix liquid handling

Analyse of PI3K/AKT/mTor translational control pathway - Application Notes

Investigating kinase activity in a cellular context

HTRF cellular assays - Scientific Presentations

Species compatibility

Cell Signaling: Biomarkers, Phospho- & total-protein assays - Flyers

Inflammation cell by cell

HTRF solutions for each cell type - Flyers

HTRF cellular phospho-protein assays

Physiologically relevant results fo fast flowing research - Flyers

Lysis buffer compatibility

Cell Signaling: Biomarkers, Phospho- & total-protein Assays - Flyers

Open R&D: Sanofi Access Platform

In collaboration with Sanofi - Scientific Presentations

Product Insert SHP2 P-Y542 Kit / 64SH2PEG-64SH2PEH

64SH2PEG-64SH2PEH - Product Insert

HTRF Product Catalog

All your HTRF assays in one document! - Catalog

A guide to Homogeneous Time Resolved Fluorescence

General principles of HTRF - Guides

Novel HTRF platform to delineate STING pathway

Explore the whole STING pathway with a single technology - Posters

How HTRF compares to Western Blot and ELISA

Get the brochure about technology comparison. - Brochures

Unleash the potential of your phosphorylation research with HTRF

A fun video introducing you to phosphorylation assays with HTRF - Videos

How to run a cell based phospho HTRF assay

3' video to set up your Phospho assay - Videos

An innate and adaptive immunity recap

Insight into the diversity of cells & signaling pathways - Guides

Advance your research on Fibrosis

Kits and reagents for Fibrosis research - Flyers

Guidelines for Cell Culture and Lysis in Different Formats Prior to HTRF Detection

Seeding and lysing recommendations for a number of cell culture vessels. - Technical Notes

Assessment of drug efficacy and toxicity by combining innovative technologies

Combination of AlphaLISA®, HTRF®, or AlphaLISA® SureFire® Ultra™ immunoassays with the ATPlite™ 1step cell viability assay - Application Notes

Methodological Aspects of Homogeneous Time-Resolved Fluorescence (HTRF)

Learn how to reduce time and sample consumption - Application Notes

Plate Reader Requirement

Choosing the right microplate reader ensures you’ll get an optimal readout. Discover our high performance reader, or verify if your lab equipment is going to be compatible with this detection technology.

Let's find your reader